427 related articles for article (PubMed ID: 23489560)
1. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations defining NSCLC subtypes and their therapeutic implications.
Pikor LA; Ramnarine VR; Lam S; Lam WL
Lung Cancer; 2013 Nov; 82(2):179-89. PubMed ID: 24011633
[TBL] [Abstract][Full Text] [Related]
5. New developments in the treatment of squamous cell lung cancer.
Filipits M
Curr Opin Oncol; 2014 Mar; 26(2):152-8. PubMed ID: 24441504
[TBL] [Abstract][Full Text] [Related]
6. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
7. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
[TBL] [Abstract][Full Text] [Related]
8. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
Hensing T; Chawla A; Batra R; Salgia R
Adv Exp Med Biol; 2014; 799():85-117. PubMed ID: 24292963
[TBL] [Abstract][Full Text] [Related]
9. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
[TBL] [Abstract][Full Text] [Related]
10. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY; Lin MW; Chang YL; Wu CT
Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N; Sato A; Watanabe T; Abe T; Nakashima C; Sueoka E; Kimura S; Sueoka-Aragane N
Lung Cancer; 2017 Aug; 110():35-41. PubMed ID: 28676216
[TBL] [Abstract][Full Text] [Related]
13. Personalizing therapy in advanced non-small cell lung cancer.
Villaruz LC; Burns TF; Ramfidis VS; Socinski MA
Semin Respir Crit Care Med; 2013 Dec; 34(6):822-36. PubMed ID: 24258572
[TBL] [Abstract][Full Text] [Related]
14. Complex analysis of the p53 tumor suppressor in lung carcinoma.
Smardova J; Liskova K; Ravcukova B; Malcikova J; Hausnerova J; Svitakova M; Hrabalkova R; Zlamalikova L; Stano-Kozubik K; Blahakova I; Speldova J; Jarkovsky J; Smarda J
Oncol Rep; 2016 Mar; 35(3):1859-67. PubMed ID: 26718964
[TBL] [Abstract][Full Text] [Related]
15. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
Oshita F; Kasajima R; Miyagi Y
J Exp Ther Oncol; 2016 Jul; 11(3):189-194. PubMed ID: 28471124
[TBL] [Abstract][Full Text] [Related]
16. Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?
Vigliar E; Malapelle U; Bellevicine C; de Luca C; Troncone G
Cytopathology; 2015 Oct; 26(5):312-7. PubMed ID: 25376259
[TBL] [Abstract][Full Text] [Related]
17. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
19. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
20. Novel therapies for advanced squamous cell carcinoma of the lung.
Koutsoukos K; Mountzios G
Future Oncol; 2016 Mar; 12(5):659-67. PubMed ID: 26880383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]